Osteopontin predicts adverse right ventricular remodelling and dysfunction in pulmonary hypertension

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 933-942

  Rosenberg, Mark ^a   Meyer, F Joachim ^b   Gruenig, Ekkehard ^c   Lutz, Matthias ^a   Lossnitzer, Dirk ^d   Wipplinger, Rita ^d   Katus, Hugo A ^d   Frey, Norbert ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Klinikum Harlaching   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biological markers; Osteopontin; Pulmonary hypertension; Right sided heart failure; Ventricular remodelling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; OSTEOPONTIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CALCULATION; CLINICAL ASSESSMENT; CORRELATION COEFFICIENT; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; UPREGULATION;

AGED; BIOLOGICAL MARKERS; COHORT STUDIES; ECHOCARDIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MODELS, THEORETICAL; OSTEOPONTIN; PREDICTIVE VALUE OF TESTS; VENTRICULAR DYSFUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84865167907     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02671.x     Document Type: Article

References (26)

1. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NF. Hyperuricemia in severe pulmonary hypertension. Chest 2000;117:19-24.
2. Torbicki A, Kurzyna M, Kuca P, Fijalkowska A, Sikora J, Florczyk M et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003;108:844-8.
3. Filusch A, Giannitsis E, Katus HA, Meyer FJ. High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clin Sci 2010;119:207-13.
4. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakamaki F et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102:865-70.
5. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537.
6. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M et al. Relationship between renal function and plasma Brain Natriuretic Peptide in patients with heart failure. J Am Coll Cardiol 2006;47:582-6.
7. Denhardt DT, Noda M, O′Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling and cell survival. J Clin Invest 2001;107:1055-61.
8. Okamoto H. Osteopontin and the cardiovascular system. Mol Cell Biochem 2007;300:1-7.
9. Singh K, Sirokman G, Communal C, Robinson KG, Conrad CH, Brooks WW et al. Myocaridal osteopontin expression coincides with the development of heart failure. Hypertension 1999;33:663-70.
10. Graf K, Do YS, Ashizawa N, Meehan WP, Giachelli CM, Marboe CC et al. Myocardial Osteopontin expression is associated with left ventricular hypertrophy. Circulation 1997;96:3063-71.
11. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:43-9.
12. Rosenberg M, Meyer FJ, Gruenig E, Lutz M, Lossnitzer D, Wipplinger R et al. Osteopontin improves risk stratification in pulmonary hypertension. Int J Cardiol 2012;155:504-5.
13. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
14. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685-713.
15. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
16. Schaefer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodeling. Cardiovasc Res 2009;82:30-9.
17. Burgess MI, Mogulkoc N, Bright-Thomas RJ, Bishop P, Egan JJ, Ray SG. Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. J Am Soc Echocardiogr 2002;15:633-9.
18. Ghio S, Pazzano AS, Klersy C, Scelsi L, Raineri C, Camporotondo R et al. Clinical and prognostic relevance of echocardiographic evaluation of right ventricular geometry in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2011;107:628-32.
19. Ghio S, Klersy C, Magrini G, D'Armini AM, Scelsi L, Raineri C et al. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2010;140:272-8.
20. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-69.
21. Kaul S, Tei C, Hopkins JM, Shah PM. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J 1984;107:526-31.
22. Lopez-Candales A, Dohi K, Rajagopalan N, Edelman K, Gulyasy B, Bazaz R. Defining normal variables of right ventricular size and function in pulmonary hypertension: an echocardiographic study. Postgrad Med J 2008;84:40-5.
23. Miller D, Farah MG, Liner A, Fox K, Schluchter M, Hoit BD. The relation between quantitative right ventricular ejection fraction and indices of tricuspid annular motion and myocardial performance. J Am Soc Echocardiogr 2004;17:443-7.
24. Tamborini G, Pepi M, Galli CA, Maltagliati A, Celeste F, Muratori M et al. Feasibility and accuracy of a routine echocardiographic assessment of right ventricular function. Int J Cardiol 2007;115:86-9.
25. Pass HI, Lott D, Leonardo F, Harbut M, Liu Z, Tang N et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353:1564-73.
26. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.